drugset / Trial / NCT02885454
To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), AL-335 and the combination of the 3-direct-acting anti-viral agents (3-DAA) ODV, AL-335, and simeprevir (SMV) on the single-dose pharmacokinetic (PK) of drospirenone and ethinylestradiol in healthy female participants.
Timeline
- Start
- 2016-08
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAFOSBUVIR | Small molecule | 800 mg | Oral |
| Subject | Odalasvir | Small molecule | 25 mg | Oral |
| Subject | Simeprevir | Small molecule | 75 mg | Oral |
| Subject | drospirenone | Unknown | 3 mg | Oral |
| Subject | ethinyl estradiol | Small molecule | 0.02 mg | Oral |
Indications
No indication recorded.